RADX Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

4.500

Open

4.450

VWAP

4.40

Vol

33.05K

Mkt Cap

52.10M

Low

4.303

Amount

145.56K

EV/EBITDA(TTM)

--

Total Shares

11.81M

EV

30.98M

EV/OCF(TTM)

--

P/S(TTM)

15.34

Radiopharm Theranostics Limited is an Australia-based clinical-stage radiotherapeutics company developing a platform of radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. The Company has a pipeline of highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer. The clinical program includes one Phase II and three Phase I trials in a variety of solid tumor cancers including lung, breast, and brain. Its technologies include Nano-mAbs, Pivalate, AVB6 Integrin, PSA-mAb, and PTPu. Nano-mAbs is a novel radiopharmaceutical platform made using genetic engineered camelid derived single domain antibodies (sdAb) labelled with a radioisotope of therapeutic radiation. Pivalate is an 18F-FPIA radiotracer, based on a short chain carbohydrate which utilizes the early steps of fatty acid oxidation.

Show More

Events Timeline

(ET)

2026-04-20

07:20:00

Radiopharm Theranostics Presents New Data on 177Lu-RAD202 at AACR Meeting

2026-04-08 (ET)

2026-04-08

07:30:00

Radiopharm Advances 177Lu-RAD202 Clinical Trial to 130mCi

2026-03-27 (ET)

2026-03-27

11:40:00

Biotech Stocks Surge in Search Activity, Radiopharm Up 2566.66%

2026-02-24 (ET)

2026-02-24

08:00:00

Radiopharm Theranostics Begins 177Lu-Betabart Clinical Trial

2026-01-28 (ET)

2026-01-28

07:20:00

Radiopharm Theranostics Reports $22.67M Net Cash Outflow for 2025

2026-01-12 (ET)

2026-01-12

07:30:00

Radiopharm Theranostics Increases Stake in Radiopharm Ventures to 87.5%

2025-12-17 (ET)

2025-12-17

11:40:00

Radiopharm Sees 17,700.84% Surge in Search Activity

2025-12-16 (ET)

2025-12-16

12:10:00

Radiopharm Sees 22,972.36% Surge in Search Activity

News

Globenewswire

04-29Globenewswire

Virtual Investor Conference Presentations Now Available Online

Globenewswire

04-23Globenewswire

Deutsche Bank to Host Depositary Receipts Investor Conference

Newsfilter

04-08Newsfilter

Radiopharm Receives Positive DSMC Recommendation to Advance Clinical Trial

NASDAQ.COM

04-07NASDAQ.COM

Radiopharm Signs Supply Agreement with Siemens Healthineers

Newsfilter

03-27Newsfilter

Radiopharm Initiates Phase 1 Trial of RAD 402 for Prostate Cancer

Newsfilter

02-24Newsfilter

Radiopharm's First Radiotherapeutic Agent Enters Clinical Trials

3 Analyst Rating

Wall Street analysts forecast RADX stock price to rise

3 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

15.00

Averages

20.33

High

30.00

Current: 0.000

Low

15.00

Averages

20.33

High

30.00

Maxim

Michael Okunewitch

NULL -> Buy

upgrade

$12 -> $15

AI Analysis

2025-12-17

Reason

Maxim

Michael Okunewitch

Price Target

$12 -> $15

AI Analysis

2025-12-17

upgrade

NULL -> Buy

Reason

Maxim analyst Michael Okunewitch raised the firm's price target on Radiopharm to $15 from $12 and keeps a Buy rating on the shares. The firm cites the company having announced positive results on its primary endpoint in an interim analysis of the first 12 patients in the Phase 2b study of RAD 101, as the study demonstrated concordance with MRI in 92% of patients treated with RAD 101 as a PET imaging agent for brain metastases, the analyst tells investors in a research note. The initial data emerging from the Phase 2b study of RAD 101 in brain metastasis imaging is highly encouraging and de-risks Radopharm's potential to address the $500M market opportunity in brain mets diagnostics and monitoring, the firm added.

B. Riley

B. Riley

Buy

maintain

$13 -> $16

2025-12-16

Reason

B. Riley

B. Riley

Price Target

$13 -> $16

2025-12-16

maintain

Buy

Reason

B. Riley raised the firm's price target on Radiopharm to $16 from $13 and keeps a Buy rating on the shares. Radiopharm reported positive interim Phase 2b imaging data for RAD101 in brain metastases, with 92% MRI concordance and clear, selective tumor uptake consistent with prior Phase 2a results, the analyst tells investors in a research note. Enrollment is over 50% in the 30-patient study, with final data expected in the first half of 2026 to inform Phase 3 design ahead of a planned FDA meeting in mid-2026, B. Riley adds.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for RADX

Unlock Now

Valuation Metrics

The current forward P/E ratio for Radiopharm Theranostics Ltd (RADX.O) is 0.00, compared to its 5-year average forward P/E of -1.05. For a more detailed relative valuation and DCF analysis to assess Radiopharm Theranostics Ltd's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-1.05

Current PE

0.00

Overvalued PE

0.07

Undervalued PE

-2.18

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

-0.66

Current EV/EBITDA

0.21

Overvalued EV/EBITDA

-0.27

Undervalued EV/EBITDA

-1.05

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

5Y Average PS

70.20

Current PS

11.03

Overvalued PS

138.80

Undervalued PS

1.60

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

top loosers which i can buy now today

Intellectia · 23 candidates

Market Cap: >= 50.00MPrice: $0.20 - $5.00Volume: >= 1,000,000Price Change Pct: <= $-8.00

Ticker

Name

Market Cap$

Odyssey Marine Exploration Inc

68.00M

Achieve Life Sciences Inc

215.60M

Ambitions Enterprise Management Co LLC

66.58M

Vertical Aerospace Ltd

346.79M

Faraday Future Intelligent Electric Inc

71.97M

Ryde Group Ltd

58.70M

Whales Holding RADX

Trading Trends

People Also Watch

Frequently Asked Questions

What is Radiopharm Theranostics Ltd (RADX) stock price today?

The current price of RADX is 4.41 USD — it has increased 3.28

What is Radiopharm Theranostics Ltd (RADX)'s business?

Radiopharm Theranostics Limited is an Australia-based clinical-stage radiotherapeutics company developing a platform of radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. The Company has a pipeline of highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer. The clinical program includes one Phase II and three Phase I trials in a variety of solid tumor cancers including lung, breast, and brain. Its technologies include Nano-mAbs, Pivalate, AVB6 Integrin, PSA-mAb, and PTPu. Nano-mAbs is a novel radiopharmaceutical platform made using genetic engineered camelid derived single domain antibodies (sdAb) labelled with a radioisotope of therapeutic radiation. Pivalate is an 18F-FPIA radiotracer, based on a short chain carbohydrate which utilizes the early steps of fatty acid oxidation.

What is the price predicton of RADX Stock?

Wall Street analysts forecast RADX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RADX is20.33 USD with a low forecast of 15.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Radiopharm Theranostics Ltd (RADX)'s revenue for the last quarter?

Radiopharm Theranostics Ltd revenue for the last quarter amounts to NaN USD, decreased

What is Radiopharm Theranostics Ltd (RADX)'s earnings per share (EPS) for the last quarter?

Radiopharm Theranostics Ltd. EPS for the last quarter amounts to USD, decreased

How many employees does Radiopharm Theranostics Ltd (RADX). have?

Radiopharm Theranostics Ltd (RADX) has 0 emplpoyees as of May 06 2026.

What is Radiopharm Theranostics Ltd (RADX) market cap?

Today RADX has the market capitalization of 52.10M USD.